Immunovant

IMVTNASDAQ

FcRn inhibition for autoantibody-mediated diseases

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.

text updated 2026-04-09, 222 days ago · archived: kept for reference, not maintained · where each field comes from

Key figures from SEC filings

We have not parsed a 10-Q or 10-K for IMVT yet, so this page shows no cash, burn or runway figure rather than an estimate. Revenue stage: Pre-revenue.

Upcoming catalysts

Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.

IMVT-1402 Graves: IMVT-1402 in Graves' disease — primary completion

2028-06

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneModerate

IMVT-1402 RA: IMVT-1402 in ACPA-positive rheumatoid arthritis — primary completion

2027-09

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneModerate

Pipeline

DrugIndicationPhaseExpected data
Batoclimabgeneralized myasthenia gravis and thyroid eye diseasePhase 3Not disclosed▼
IMVT-1402multiple autoimmune diseasesPhase 2Not disclosed▼

Analysis

We have not yet written an analysis of Immunovant that is specific and current enough to publish. Earlier text here was removed rather than left up: on most profiles it was a template shared with other companies, and where a correction is listed above, it was written before the facts changed. The filing figures, pipeline and sourced catalysts on this page are current; the written thesis will be added from them.
Trade IMVT commission-free on Webullvia Webull · Affiliate

Comparable companies

argenxUCBCartesian Therapeutics

Sponsored

Get premium IMVT analysis on Seeking Alpha

Affiliate link — we may earn a commission at no cost to you

Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.

Sponsor's late-stage trial record

Immunovant has 19 Phase 2 or 3 studies on ClinicalTrials.gov: 5 completed, 6 stopped early, 8 ongoing.

5

Completed

6

Stopped early

8

Ongoing

Stopped early

  • NCT07188844Phase 2 · started 2025 · terminated

    Batoclimab in chronic inflammatory demyelinating polyneuropathy · n=26

    Reason given: Sponsor Decision

  • NCT05581199Phase 2 · started 2022 · terminated

    Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly in chronic inflammatory demyelinating polyneuropathy · n=94

    Reason given: Sponsor Decision

  • NCT05517447Phase 3 · started 2022 · terminated

    Observational cohort study in thyroid eye disease · n=109

    Reason given: The feeder studies (i.e., IMVT-1401-3201 and 3202) for study IMVT-1401-3203 failed to achieve their pre-defined primary efficacy outcomes. Accordingly, there was a change to the benefit-risk balance. No new safety findings were observed.

  • NCT05403541Phase 3 · started 2022 · terminated

    Batoclimab 680 mg SC weekly in generalized myasthenia gravis · n=233

    Reason given: Sponsor Decision

  • ASCEND-WAIHAPhase 2 · started 2020 · terminated

    RVT-1401 680 mg/weekly in warm autoimmune hemolytic anemia · n=5

    Reason given: Sponsor decision

  • NCT03938545Phase 2 · started 2019 · terminated

    RVT-1401 (Administered via subcutaneous injection) in graves' ophthalmopathy (go) · n=65

    Reason given: Sponsor decision based on premature unblinding of treatment allocations necessitated by program-wide review

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.